NasdaqGS:TSHABiotechs
Taysha Gene Therapies Advances Rett Program As Valuation Draws Investor Focus
Taysha Gene Therapies (NasdaqGS:TSHA) received FDA Breakthrough Therapy designation for TSHA-102 in Rett syndrome.
The company reported a 100% patient response rate in pivotal Phase I/II data for TSHA-102.
Regulators aligned with Taysha on pivotal trial designs for its lead Rett syndrome program.
Taysha added a key commercial hire as it prepares for potential TSHA-102 commercialization.
Taysha Gene Therapies, trading at $4.4 per share, has been drawing attention as its 1 year return stands...